My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}

Want to join the conversation?

$HUM {{ '2015-07-29T12:05:49+0000' | timeago}} • Announcement

$HUM 2Q15 PR: Diluted EPS for the quarter was $2.85 compared to $2.19MM in 2Q14. In April 2015, the company’s BoD declared a cash dividend of $0.29 per share, totaling $43MM in the aggregate, payable on July 31, 2015 to stockholders of record on June 30, 2015. Shares used in computing diluted EPS were 151.148MM compared to 157.046MM in 2Q14.

User Vishnu Beri {{ '2016-10-25T21:15:45+0000' | timeago}}

Apple ($AAPL) reported decline in sales and profits from comparable quarter last year, attributing the decline to announcement of iPhone 7/7s. Sales and profit are being guided higher for next quarter. Apple is a solid company and will continue to dominate tech and consumer electronics segment for a while. Personally, looks like there is little downside in this investment.

User Mark Collas {{ '2016-10-25T20:12:01+0000' | timeago}}

Waiting with fingers crossed for $AAPL’s fourth quarter earnings.

User RC xNair {{ '2016-10-25T17:04:47+0000' | timeago}}

Looking ahead to $AAPL earnings release later in the afternoon today? Gene Munster, analyst from Piper Jaffrey and the most respected authority for Apple, had this to say - "The second and slightly larger group of investors believe the tail of the iPhone 7 is irrelevant, and is betting that the iPhone 10th Anniversary will yield a jump in growth from flat to up ~15%."

User Carlton Davis {{ '2016-10-24T19:31:20+0000' | timeago}}

$COL agreed to buy $BEAV for $6.4 billion in cash and stock. Also Rockwell Collins reported higher 4Q16 earnings on growth in Government Systems and higher revenue in Information Management Services.

User Charles Elliston {{ '2016-10-24T19:15:21+0000' | timeago}}

Wow! What a buzz the $T-$TWX deal is making! Almost everyone from politicians to competitors have come out against this deal. Even Wall Street doesn’t seem to be too thrilled. Both stocks were down today.

$BIIB {{ '2016-10-26T13:15:56+0000' | timeago}} • Webcast

$BIIB's Tysabri worldwide revenue was $515MM in 3Q16, an increase of 7% versus last year. This included $301MM in the US and $214MM outside the US. Tysabri revenue outside the US benefited by $20MM, due to a favorable adjustment to the company's discounts in allowances. ForEx and the hedge impact weakened Tysabri sales by approx. $16MM versus 3Q15.

$CMCSA {{ '2016-10-26T13:13:33+0000' | timeago}} • Webcast

$CMCSA's consolidated Capex increased 11.1% to $2.4Bil in 3Q16. During 3Q16, the company paid dividends totaling $663MM and repurchased 20.8MM of its common shares for $1.4Bil.

$BIIB {{ '2016-10-26T13:13:06+0000' | timeago}} • Webcast

$BIIB stated that Interferon revenues, including both Avonex and Plegridy, were $708MM during 3Q16, a decrease of 10% versus last year. This included $506MM in the US and $203MM in sales outside the US. In the US, there was a drawdown of Avonex inventory in the wholesale channel, resulting approx. $10MM versus 2Q16.

$NSC {{ '2016-10-26T13:10:58+0000' | timeago}} • Announcement

$NSC's Intermodal revenues for 3Q16 fell by 7% from last year. Volume declined by 1% due to lower Triple Crown Services volume, a result of last year's restructuring. Coal revenues dropped 18% as above-normal stockpiles and low natural gas prices combined to decrease volume by 15%.

$BIIB {{ '2016-10-26T13:10:31+0000' | timeago}} • Webcast

$BIIB's global Tecfidera revenues were $1.034Bil, an increase of 10% versus 3Q15. This included revenues of $845MM in the US, an increase of 12% versus last year, and $189MM outside the US, an increase of 3% versus a year ago. In the US, Tecfidera benefited by approx. $40-50MM versus 2Q16, due to inventory build in the channel.